ArticleMolecular systems biology2018
Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer.
Article in Molecular systems biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.Prostate cancer and prostatic diseases · 2020Pooled it
- Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer.NPJ precision oncology · 2025Article
- BUB1-based risk model predicts prostate cancer prognosis and reveals therapeutic vulnerabilities.European journal of medical research · 2025Article
- The yin and yang of chromosomal instability in prostate cancer.Nature reviews. Urology · 2024Review
- Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients.Discover oncology · 2023Article
- Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer.iScience · 2023Article
- Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer.Cell reports. Medicine · 2023Article
- Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens.PloS one · 2023Article
- The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.Oncogene · 2022Article
- Molecular Characteristics and Prognostic Role of MFAP2 in Stomach Adenocarcinoma.Journal of healthcare engineering · 2022Article
- Multi-omics analysis defines 5-fluorouracil drug resistance in 3D HeLa carcinoma cell model.Bioresources and bioprocessing · 2021Article
- A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells.Oncogene · 2021Article
- Hypermethylation and Downregulation of UTP6 Are Associated With Stemness Properties, Chemoradiotherapy Resistance, and Prognosis in Rectal Cancer: A Co-expression Network Analysis.Frontiers in cell and developmental biology · 2021Article
- Association study between genetic variants in retinol metabolism pathway genes and prostate cancer risk.Cancer medicine · 2020Article
- Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients.International journal of oncology · 2020Article
- FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis.Frontiers in genetics · 2020Article
- Oncogenic Network and Hub Genes for Natural Killer/T-Cell Lymphoma Utilizing WGCNA.Frontiers in oncology · 2020Article
- Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model.Frontiers in cell and developmental biology · 2020Article
- A Four Gene-Based Risk Score System Associated with Chemoradiotherapy Response and Tumor Recurrence in Rectal Cancer by Co-Expression Network Analysis.OncoTargets and therapy · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Identifying critical pathways governing disease progression is essential for accurate prognosis and effective therapy. We developed a broadly applicable and novel systems-level gene discovery strategy. This approach focused on constitutively active androgen receptor (AR) splice variant-driven pathways as representative of an intractable mechanism of prostate cancer (PC) therapeutic resistance. We performed a meta-analysis of human prostate samples using weighted gene co-expression network analysis combined with experimental AR variant transcriptome analyses. An AR variant-driven gene module that is upregulated during human PC progression was identified. We filtered this module by identifying genes that functionally interacted with AR variants using a high-throughput synthetic genetic array screen in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.